Inflammatory Breast Cancer Staging

TNM Classification

The American Joint Committee on Cancer (AJCC) recommends using the TNM system for staging inflammatory breast cancer, which is defined as T4d, with N staging based on lymph node involvement 1, 2, 3, 4, 5, 6, 7
Inflammatory breast cancer is always classified as T4d, with N staging based on lymph node involvement 1, 2, 3, 4, 5, 6, 7
The N staging is based on the presence of lymph node involvement, with metastatic disease classified as Stage IV 1, 2, 3, 4, 5, 6, 7
Non-metastatic patients are classified as Stage IIIB, while metastatic patients are classified as Stage IV 1, 2, 3, 4, 5, 6, 7

The American College of Radiology recommends diagnostic mammography and breast ultrasound for all inflammatory breast cancer patients, with typical findings including skin thickening and trabecular distortion 1, 2, 3, 4, 5, 6, 7
Computed tomography (CT) and bone scintigraphy are recommended for all inflammatory breast cancer patients to evaluate for distant metastases 1, 4
PET/CT is particularly useful for detecting internal mammary lymph node involvement, but has limited availability and high cost 1, 4

The American Society of Clinical Oncology recommends that the basal TNM staging be recorded based on clinical parameters, due to the standard treatment of preoperative systemic chemotherapy 1, 2, 3, 4, 5, 6, 7
Breast MRI is not routinely recommended, but may be used in cases where mammography or ultrasound are unable to detect breast parenchymal lesions, or as part of clinical trials 1, 2, 3, 4, 5, 6, 7

The American Cancer Society emphasizes that determining the stage at diagnosis is critical for treatment planning, as surgical and radiation therapy decisions are based on the extent of disease 4, 5, 7
Inflammatory breast cancer has a high risk of systemic spread, even in localized disease, and therefore requires a multimodal treatment approach, including neoadjuvant chemotherapy, surgery, and radiation therapy 4, 5, 7